Haleon Heads These 3 British AI Healthcare Stocks

National Grid’s plan for the UK’s largest electricity substation on Teesside, built to support a nearby AI datacentre, shows how serious the country is about AI infrastructure. Healthcare is one of the clearest beneficiaries, as better data centres make complex medical AI tools more practical. This article highlights 3 UK listed AI healthcare stocks from our screener that tap directly into that theme.

The three stocks highlighted below are only a starting sample, as the full screening work turned up 6 more AI healthcare companies with equally compelling stories that are not covered here.

If you want to identify your own high conviction ideas across this theme, head straight to the Transformative Artificial intelligence (AI) Healthcare Stocks screener to filter and analyze the wider field of contenders.

Haleon (LSE:HLN)

Overview: Haleon is a global consumer healthcare group that uses a Microsoft AI partnership to sharpen product development and personalized OTC health offerings.

Operations: Haleon generates about £3.8b from North America, £4.7b across EMEA and Latam, and £2.6b from Asia Pacific markets.

Market Cap: £28.1b

Haleon brings the AI healthcare theme down to earth, using data tools to reshape everyday oral care, pain relief and wellness decisions for millions of households.

"Delivery of the £800m gross cost savings and operating model programs, including 27% SKU and 26% formulation reductions and early benefits from AI tools that have improved forecast accuracy by 5 to 6%, underpins the recent 140 basis points gross margin expansion and provides a visible path for further net margin and earnings improvement."

For long term holders, a single unseen pressure on those efficiency gains could be the swing factor that decides Haleon’s margin story.

That unseen pressure is only one thread in the full narrative for Haleon, which also maps where Haleon’s AI efficiency push could accelerate or quietly stall the margin story.

Abingdon Health (AIM:ABDX)

Overview: Abingdon Health develops and manufactures lateral flow diagnostics, and its Appdx smartphone reader and related AI health software anchor its role in AI-driven testing.

Operations: Abingdon Health generates about £5.0 million from Contract Development, £4.1 million from Regulatory services, £1.3 million from Contract Manufacturing and £0.6 million from Product Sales across Europe, the USA and Canada, the UK and other regions.

Market Cap: £39.2 million

Abingdon Health matters for this AI healthcare theme because Appdx turns everyday lateral flow strips into data rich tools that plug straight into digital decision making for clinicians and test providers.

"Growing use of digital tools in diagnostics, including smartphone based test readers, aligns with Abingdon’s AppDx platform, which can turn standard lateral flow tests into quantifiable, software linked products and may support higher value contracts and improved gross margins."

For investors, one unresolved funding and profitability question could determine whether that Appdx driven opportunity translates into durable margins or remains stuck in development.

That funding hinge is exactly why the full narrative for Abingdon Health weighs how Appdx contracts, capital needs and AI adoption could be accelerating or quietly stalling the Abingdon Health equity story.

AstraZeneca (LSE:AZN)

Overview: AstraZeneca is a global biopharmaceutical group that develops and sells prescription medicines for cancer, heart and metabolic disease, respiratory conditions, vaccines, immune therapies, and rare disorders.

Market Cap: £216.5b

AstraZeneca brings the AI healthcare theme to large scale drug development by using partnerships to apply advanced models across oncology, safety and trial design.

"The company's robust and diversified late-stage pipeline, particularly in oncology, rare diseases, and cardiovascular or metabolic therapies, is now underpinned by management's disclosure of 12 programs each with risk adjusted peak sales potential above US$5b and several more in the US$3b to US$5b range."

For investors, what happens if a single assumption inside those AI supported development bets fails could reshape both future earnings and valuation power.

If that single misfiring assumption worries you, the full narrative for AstraZeneca shows where AstraZeneca’s AI bets could be accelerating value or quietly stalling expectations.

Seeking Alternatives Before The Crowd?

Fresh ideas often move first, and slow research can end up chasing momentum after prices start moving. Scan curated shortlists while it matters and position yourself earlier in the process.

• Spot steady cash generators before yield hunters pile in by scanning the 5 dividend fortresses, which is built to highlight income opportunities that may still be under the radar for now.
• Track fast-moving automation plays by running the 95 robotics and automation stocks, which filters for businesses tied to real-world adoption instead of focusing on areas where enthusiasm may already be fading.
• Target companies with resilient balance sheets through the list of solid balance sheet and fundamentals (10 results) so you can focus on financial strength while prices are still settling.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com